Benzamycin Shortage: What Providers and Prescribers Need to Know in 2026

If your patients are reporting difficulty filling Benzamycin prescriptions, the problem is systemic — not isolated. While Benzamycin (erythromycin 3%/benzoyl peroxide 5% topical gel) is not formally listed on the FDA Drug Shortage Database, real-world availability is inconsistent across the country. This briefing covers the current state of Benzamycin supply, the structural factors driving the issue, clinical alternatives, and tools to help your patients access their acne medication.

Current Supply Status (Early 2026)

Benzamycin is not in an official FDA-declared shortage as of early 2026. However, pharmacy-level stockouts are common, and patients may need to contact multiple pharmacies before locating their prescription. Both the brand-name product (Bausch Health US, LLC) and the generic erythromycin/benzoyl peroxide 3%/5% gel (produced by companies including Rising Pharmaceuticals) remain on the market.

The supply situation is most acute at large chain pharmacies, which may not routinely stock Benzamycin due to lower prescription volume. Independent pharmacies typically have better sourcing flexibility.

Structural Factors Behind Benzamycin's Availability Challenges

Understanding the root causes helps set realistic expectations for your patients and informs prescribing decisions:

• Cold-chain and reconstitution requirements: Benzamycin must be reconstituted by the pharmacist. After mixing, the gel requires refrigeration (2°C–8°C) and has a 3-month expiration. This creates stocking friction and waste risk for pharmacies that don't have consistent demand.
• Declining market share: Clindamycin-based combination products have largely supplanted erythromycin-based options as first-line topical treatment per AAD guidelines. As Benzamycin prescribing volume has decreased, fewer pharmacies carry routine stock.
• Limited generic manufacturing base: A small number of manufacturers produce generic erythromycin/benzoyl peroxide gel. Any production disruption at one manufacturer creates disproportionate downstream impact.
• API supply chain vulnerability: Active pharmaceutical ingredients for erythromycin are largely sourced from overseas suppliers. International supply chain disruptions can affect domestic availability with little advance warning.

Resistance Considerations When Prescribing Benzamycin

The combination of erythromycin with benzoyl peroxide is designed in part to reduce the risk of antibiotic resistance — benzoyl peroxide suppresses resistant Cutibacterium acnes strains. However, erythromycin resistance rates in C. acnes have increased significantly over the past two decades. Current AAD guidelines note that clindamycin carries a slightly lower resistance risk than erythromycin for topical acne therapy. If you're prescribing Benzamycin today, it is appropriate for patients with known erythromycin susceptibility or those who have previously responded well. For new starts, a clindamycin/BPO combination may be a more durable choice.

Clinical Alternatives If Benzamycin Is Unavailable

When Benzamycin is not accessible, consider the following alternatives based on your patient's acne type and history:

• Clindamycin/benzoyl peroxide (BenzaClin 1%/5%, Acanya 1.2%/2.5%, Onexton 1.2%/3.75%): The most direct substitute; widely available at major chains; slightly lower resistance risk; same dual-mechanism approach. Note: some formulations (e.g., BenzaClin) require refrigeration; Acanya and Onexton do not.
• Adapalene/benzoyl peroxide (Epiduo 0.1%/2.5%, Epiduo Forte 0.3%/2.5%): Non-antibiotic combination; retinoid + BPO; appropriate for mixed comedonal-inflammatory acne; no resistance concern; Epiduo 0.1%/2.5% is now OTC.
• Dapsone 5% or 7.5% gel (Aczone): Anti-inflammatory antibiotic; particularly effective for adult female inflammatory acne; no bleaching; once-daily 7.5% formulation available.
• Topical retinoids (tretinoin, adapalene): First-line for comedonal acne; often combined with a topical antimicrobial for mixed presentations; tretinoin has long-term safety data.

Prescribing Guidance to Minimize Fill Barriers

When prescribing Benzamycin, several steps can reduce the chance of a failed fill for your patients:

1. Allow generic substitution on your prescription. The generic is therapeutically equivalent, more available, and costs roughly $31 with coupons vs. $130+ for brand.
2. Advise patients to try independent pharmacies first. They tend to have better Benzamycin availability than large chains.
3. Write a contingency alternative on the prescription (e.g., "If Benzamycin unavailable, may substitute clindamycin 1%/benzoyl peroxide 5% gel") — subject to your state's prescribing rules.
4. Direct your patients to medfinder for providers — a tool that calls nearby pharmacies to check current Benzamycin stock and texts results to your patient.

Patient Assistance and Cost Resources

Cost barriers compound the access challenge. The retail price for brand Benzamycin ranges from $130 to $490+ for a 46.6g jar depending on the pharmacy. Generic erythromycin/benzoyl peroxide gel is significantly cheaper — approximately $31 with GoodRx or $50 with SingleCare coupons. For uninsured or underinsured patients, the Arbor Pharmaceuticals Patient Assistance Program (via pparx.org) can provide a 3-month supply at no charge to eligible patients.

For more guidance on supporting your patients through Benzamycin fill difficulties, see how to help your patients find Benzamycin in stock: a provider's guide.